Hadlima

Drug Overview

In the specialized field of Gastroenterology, the management of chronic, immune-mediated inflammatory conditions has been revolutionized by the advent of advanced therapeutic agents. Hadlima is a prominent medication within this category, specifically classified under the TNF-Alpha Inhibitor drug class. As a Biologic medication, it is engineered to target the underlying biological processes that drive persistent inflammation in the digestive tract.

Hadlima is a Monoclonal Antibody that serves as a biosimilar to the reference product Humira. This means it has undergone rigorous testing to demonstrate that it is highly similar in terms of safety, purity, and potency to the original biologic. For patients navigating the complexities of acute or chronic digestive disorders, Hadlima offers a Targeted Therapy approach, aiming not only to suppress symptoms but to achieve deep tissue healing and long-term remission.

• Generic Name: Adalimumab-bwwd
• US Brand Names: Hadlima (available in both citrate-buffered and citrate-free formulations)
• Route of Administration: Subcutaneous (SC) injection
• FDA Approval Status: FDA-approved for the treatment of various inflammatory conditions, including Crohn’s disease and Ulcerative Colitis.

What Is It and How Does It Work? (Mechanism of Action)

Hadlima functions as a Targeted Therapy by precisely interfering with the body’s inflammatory signaling pathway. In patients with conditions like Crohn’s disease or Ulcerative Colitis, the immune system overproduces a specific protein known as Tumor Necrosis Factor-alpha (TNF-alpha). This protein acts as a primary chemical messenger that sends signals to various cells to initiate and sustain inflammation. While TNF-alpha is necessary for a healthy immune response to infections, its overabundance in the gastrointestinal tract leads to the destruction of the intestinal lining, causing ulcers, bleeding, and severe pain.

At the molecular and physiological level, Hadlima is a recombinant human IgG1 Monoclonal Antibody. It works by identifying and binding specifically to TNF-alpha molecules circulating in the blood and those bound to cell surfaces. By “locking” onto these proteins, Hadlima physically blocks them from attaching to the TNF receptors (p55 and p75) located on the surface of inflammatory cells.

This TNF-alpha inhibition results in several critical therapeutic outcomes:

1. Cytokine Modulation: It reduces the production of other pro-inflammatory chemicals that contribute to tissue damage.
2. Reduction of Cell Infiltration: It prevents the migration of white blood cells into the inflamed areas of the gut.
3. Mucosal Healing: By silencing the inflammatory “alarm,” the drug allows the intestinal epithelial barrier to repair itself, potentially reversing the damage caused by the disease.

FDA-Approved Clinical Indications

Primary Indication

Hadlima is primarily indicated for reducing signs and symptoms, and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease and Ulcerative Colitis. It is typically utilized when patients have had an inadequate response to conventional treatments like corticosteroids or immunosuppressants.

Other Approved & Off-Label Uses

Beyond its role in Gastroenterology, the systemic nature of TNF-alpha allows Hadlima to be used for various other inflammatory conditions:

• Rheumatoid Arthritis (RA): To reduce pain and joint swelling.
• Psoriatic Arthritis (PsA): To manage both skin symptoms and joint inflammation.
• Ankylosing Spondylitis (AS): For the treatment of inflammatory arthritis of the spine.
• Plaque Psoriasis: To clear skin lesions and reduce inflammation.
• Hidradenitis Suppurativa: For the management of chronic skin abscesses.
• Uveitis: To treat non-infectious inflammation of the eye.
• Primary Gastroenterology Indications:
  • Crohn’s Disease: Targets deep-penetrating inflammation to prevent complications like fistulas or strictures.
  • Ulcerative Colitis: Restores the integrity of the colonic mucosa to stop rectal bleeding and frequency.

Dosage and Administration Protocols

The administration of Hadlima requires a specific “loading” phase to rapidly bring the disease under control, followed by a “maintenance” phase to keep the inflammation suppressed. The medication is delivered via a subcutaneous injection, which can be performed by the patient or a caregiver at home using a prefilled syringe or an autoinjector.

Indication	Standard Induction Dose	Maintenance Dose	Frequency
Crohn’s Disease (Adult)	160 mg on Day 1; 80 mg on Day 15	40 mg	Every other week (starting Day 29)
Ulcerative Colitis (Adult)	160 mg on Day 1; 80 mg on Day 15	40 mg	Every other week (starting Day 29)
Pediatric Crohn’s (17kg to <40kg)	80 mg on Day 1; 40 mg on Day 15	20 mg	Every other week (starting Day 29)

Dose Adjustments and Specific Populations:

• Hepatic/Renal Insufficiency: No specific dose adjustments are required for patients with hepatic or renal impairment (Child-Pugh score not applicable for clearance of biologics), as Monoclonal Antibodies are cleared via the reticuloendothelial system rather than the liver or kidneys.
• Elderly Patients: While no specific dose change is mandated, patients over 65 should be monitored closely for an increased risk of infection.
• Maintenance Titration: In some cases of “loss of response,” a physician may increase the frequency to 40 mg every week, though this is an individualized clinical decision.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical research spanning 2020-2026 has confirmed that Hadlima provides equivalent therapeutic outcomes to its reference biologic. In pivotal clinical trials for Ulcerative Colitis, patients treated with this Monoclonal Antibody demonstrated significant improvements in clinical remission rates. By Week 8 of induction, data indicated that approximately 18% to 20% of patients achieved full clinical remission compared to placebo groups.

In the management of Crohn’s disease, efficacy is often measured by the Crohn’s Disease Activity Index (CDAI). Research results show that a majority of patients experience a reduction of 100 points or more in their CDAI score within the first month of treatment. Furthermore, long-term studies emphasize the importance of Mucosal Healing. Endoscopic scoring (such as the Mayo Score for UC) has shown that up to 30% of patients achieve a score of 0 or 1—indicating a nearly normal-looking intestinal lining—after one year of maintenance therapy. This numerical data underscores the drug’s ability to fundamentally change the disease trajectory for many patients.

Safety Profile and Side Effects

Black Box Warning: Hadlima carries a Black Box Warning regarding the risk of serious infections and malignancy. Patients are at an increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections. Additionally, cases of lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients using TNF blockers.

Common side effects (>10%)

• Injection Site Reactions: Redness, itching, pain, or swelling at the site of the needle stick.
• Upper Respiratory Infections: Common cold symptoms, sinus infections, or sore throat.
• Headache: Mild to moderate tension-style headaches.
• Rash: Generalized skin irritation.

Serious adverse events

• Hepatotoxicity: Reactivation of Hepatitis B or rare cases of acute liver failure.
• Neurological Reactions: Exacerbation or new onset of demyelinating disease (e.g., Multiple Sclerosis).
• Heart Failure: New onset or worsening of existing congestive heart failure.
• Lupus-like Syndrome: Development of auto-antibodies leading to joint pain and rashes.

Management Strategies

Patients should be monitored for signs of infection, such as fever or persistent cough. If a serious infection develops, the Biologic should be discontinued until the infection is resolved. Injection site discomfort can often be mitigated by using the citrate-free formulation or allowing the medication to reach room temperature before injection.

Connection to Mucosal Immunology and Microbiome Research

Modern research in Gastroenterology has begun to focus on how Biologic therapies like Hadlima interact with the complex ecosystem of the gut. The intestinal epithelial barrier acts as a gatekeeper; when it is compromised by TNF-alpha, the “leaky gut” allows bacteria to interact with the gut-associated lymphoid tissue (GALT), further fueling the fire of inflammation.

By inducing TNF-alpha inhibition, Hadlima helps restore the integrity of the tight junctions between cells in the intestinal wall. Studies suggest that as the mucosa heals, the gut microbiome begins to shift from a pro-inflammatory state to a more diverse and balanced composition. This suggests that the drug does not just suppress the immune system; it helps restore the ecological balance within the digestive tract, which is critical for long-term health and the prevention of disease flares.

Disclaimer: Research regarding the use of motility agents like loperamide to intentionally shift microbial diversity or “reset” the gut environment is currently in the investigative phase and is not yet standard clinical practice; all treatment protocols must be individualized by a qualified healthcare professional. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A complete colonoscopy or endoscopy to document disease activity and baseline mucosal scores.
• Specialized Testing: Screening for latent Tuberculosis (TB) via PPD or QuantiFERON gold test and screening for Hepatitis B is mandatory.
• Organ Function: Baseline Liver Function Tests (LFTs) and Complete Blood Count (CBC).
• Screening: Checking for nutritional deficiencies such as Vitamin B12, Iron, and Vitamin D.

Monitoring and Precautions

• Vigilance: Continuous monitoring for “loss of response.” If symptoms return, a physician may use therapeutic drug monitoring to check for anti-drug antibodies.
• Lifestyle: Smoking cessation is absolutely critical, as smoking significantly reduces the efficacy of TNF blockers in Crohn’s disease.
• Hydration: Maintaining adequate hydration is essential during flares.

“Do’s and Don’ts” list

• DO store Hadlima in the refrigerator but allow it to sit at room temperature for 15-30 minutes before injecting.
• DO rotate your injection sites (abdomen or thighs) to prevent skin hardening.
• DON’T receive live vaccines (such as MMR or Yellow Fever) while taking this medication.
• DON’T skip doses even if you feel completely healthy, as this can lead to the formation of antibodies against the drug.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice from a qualified healthcare provider. Hadlima is a potent immunosuppressant, and treatment should be closely supervised by a specialist in Gastroenterology. Always consult your doctor regarding any symptoms or side effects you experience while on this medication.